Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
17.04. | Celldex Hails Enrolment News, Shares Poke Ahead | 1 | Baystreet.ca | ||
17.04. | Celldex Therapeutics, Inc.: Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria | 77 | GlobeNewswire (Europe) | HAMPTON, N.J., April 17, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that patient enrollment has been completed in the Company's Phase 2 clinical study of barzolvolimab... ► Artikel lesen | |
08.03. | Celldex Therapeutics, Inc.: Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference | 5 | GlobeNewswire (USA) | ||
05.03. | Celldex Therapeutics, Inc.: Celldex Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference | 2 | GlobeNewswire (USA) | ||
05.03. | Celldex Therapeutics, Inc.: Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares | 2 | GlobeNewswire (USA) | ||
01.03. | Celldex announces $400.4 million public stock offering | 7 | Investing.com | ||
01.03. | Celldex prices $400.4M stock offering | 4 | Seeking Alpha | ||
01.03. | Celldex Therapeutics Prices Public Offering Of 8.52 Mln Shares At $47.00/shr | 375 | AFX News | WASHINGTON (dpa-AFX) - Celldex Therapeutics Inc. (CLDX) announced the pricing of an upsized underwritten public offering of 8.52 million shares of its common stock at a public offering price... ► Artikel lesen | |
01.03. | Celldex Therapeutics, Inc.: Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock | 3 | GlobeNewswire (USA) | ||
28.02. | Celldex plans $250 million public stock offering | 3 | Investing.com | ||
28.02. | Celldex Therapeutics, Inc.: Celldex Therapeutics Announces Proposed Public Offering of Common Stock | 2 | GlobeNewswire (USA) | ||
26.02. | Celldex Stock Hits 11-Month High, Up 19%, On A Promising New Hives Treatment | 9 | Investor's Business Daily | ||
26.02. | Celldex shares up 3.5% after posting revenue beat | 7 | Investing.com | ||
26.02. | Celldex Therapeutics Inc reports results for the quarter ended in December - Earnings Summary | 5 | Reuters | ||
26.02. | Celldex GAAP EPS of -$0.83 misses by $0.09, revenue of $4.13M beats by $3.27M | 1 | Seeking Alpha | ||
26.02. | Celldex Therapeutics, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
26.02. | Celldex Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
26.02. | Celldex Therapeutics, Inc.: Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update | 230 | GlobeNewswire (Europe) | - Phase 3 CSU studies expected to initiate in summer 2024 -- Positive Phase 2 CSU 12 week data reported in late breaking oral presentation at AAAAI 2024; 52 week data to be reported in 2H 2024 --... ► Artikel lesen | |
24.02. | Celldex Therapeutics, Inc.: Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria | 169 | GlobeNewswire (Europe) | - Primary and secondary endpoints met with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose groups -- Sustained activity with rapid... ► Artikel lesen | |
06.02. | Celldex Therapeutics, Inc.: Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference | 3 | GlobeNewswire (USA) |
Suchbegriffe der letzen 24 h | Anzahl |
---|---|
EVOTEC | 4.110 |
NEL | 1.958 |
NVIDIA | 1.690 |
DEUTSCHE BANK | 1.583 |
BAYER | 1.360 |
BASF | 1.257 |
MICROSOFT | 1.257 |
ALPHABET | 1.246 |
TUI | 1.200 |
TESLA | 1.152 |
SUPER MICRO COMPUTER | 1.084 |
BYD | 1.064 |
RHEINMETALL | 1.032 |
DELIVERY HERO | 1.028 |
INTEL | 856 |
AIXTRON SE | 837 |
META PLATFORMS | 796 |
COMMERZBANK | 793 |
AMAZON | 745 |
VARTA | 648 |
RENK GROUP | 571 |
PLUG POWER | 555 |
HELLOFRESH | 495 |
NEWMONT | 420 |